Tutorials › Econometrics (Graduate) › Treatment-Effect Heterogeneity and 2SLS Weights

Instrumental Variables in Causal Analysis · Tutorial 856 of 952

Treatment-Effect Heterogeneity and 2SLS Weights

Learn when covariate-adjusted 2SLS is a weighted average of stratum-specific complier effects, how to calculate its weights, and when those weights cease to have a causal interpretation.

Advanced 12 min read

What You'll Learn

  • Define the covariate-adjusted 2SLS estimand for one binary instrument and saturated covariate strata
  • Derive its stratum weights from the residualized instrument
  • Relate each stratum’s reduced form and first stage to its complier average causal effect
  • Identify when the resulting weights are nonnegative and sum to one
  • Recognize zero-first-stage strata without assigning them undefined local effects
  • Diagnose why misspecified covariate adjustment can undermine the LATE-weight interpretation

Why 2SLS Weights Matter

An instrumental-variable estimate is often reported as a single coefficient. When treatment effects differ across people, that coefficient need not represent an average effect for the whole population. With a binary instrument and covariates, its interpretation depends on which covariate strata experience instrument-induced changes in treatment, and on how much variation in the instrument occurs within each stratum.

This tutorial derives that interpretation for a specific setting: one binary instrument, a binary treatment, and a finite set of covariate strata included as saturated controls in 2SLS. Under the relevant instrumental-variable assumptions, the coefficient is a weighted average of stratum-specific local average treatment effects (LATEs). The weights are nonnegative under monotonicity, but they are not generally the population shares of the strata or the shares of all compliers.

Setup and Assumptions

Let \(Z\in\{0,1\}\) be an instrument, \(D\in\{0,1\}\) treatment, and \(Y\) the outcome. Let \(X\) be a covariate that takes values in a finite set of strata \(x\). Write \(\pi_x=P(X=x)\) and \(q_x=P(Z=1\mid X=x)\). For each stratum, define the reduced-form and first-stage differences

$$ \Delta Y_x=E[Y\mid Z=1,X=x]-E[Y\mid Z=0,X=x], \qquad \Delta D_x=E[D\mid Z=1,X=x]-E[D\mid Z=0,X=x]. $$

The potential treatment under instrument value \(z\) is \(D(z)\), and the potential outcome under treatment value \(d\) is \(Y(d)\). The assumptions used below are conditional independence of the instrument, exclusion, monotonicity, and overlap within the covariate strata.

Assumptions: Within each stratum \(X=x\), the instrument is independent of the potential treatments and outcomes: \(Z\perp (D(0),D(1),Y(0),Y(1))\mid X\). The instrument affects the outcome only through treatment, so the observed outcome is \(Y=Y(D)\). Monotonicity holds: \(D(1)\ge D(0)\) for every individual. For a stratum included in the analysis, \(0<q_x<1\), and \(\pi_x>0\). These conditions support a stratum-specific LATE interpretation; they do not imply that the instrument is randomly assigned unconditionally across all strata.

The four principal strata are defined by \((D(0),D(1))\): never-takers \((0,0)\), always-takers \((1,1)\), compliers \((0,1)\), and defiers \((1,0)\). Monotonicity rules out defiers. In a stratum with a positive first stage, the stratum-specific LATE is

$$ \tau_x=E[Y(1)-Y(0)\mid D(1)>D(0),X=x]. $$

This parameter is defined only if there are compliers in stratum \(x\), equivalently if \(\Delta D_x>0\) under the assumptions. That distinction will matter when some strata have no instrument-induced treatment change.

From Stratum Differences to a 2SLS Coefficient

Consider 2SLS for the regression of \(Y\) on \(D\) and saturated indicators for \(X\), using \(Z\) and those same indicators as instruments. Saturation means that the controls allow a separate intercept for every stratum. By the Frisch–Waugh–Lovell residualization principle, the coefficient is the ratio of the covariance of the residualized instrument with \(Y\) to its covariance with \(D\).

Within stratum \(x\), the residualized instrument is \(Z-q_x\). Its conditional covariance with any variable \(V\) is

$$ E[(Z-q_x)V\mid X=x] =q_x(1-q_x)\{E[V\mid Z=1,X=x]-E[V\mid Z=0,X=x]\}. $$

To verify this identity, expand the left side as \(E[ZV\mid x]-q_xE[V\mid x]\). Since \(Z\) is binary, \(E[ZV\mid x]=q_xE[V\mid Z=1,x]\), while \(E[V\mid x]=q_xE[V\mid Z=1,x]+(1-q_x)E[V\mid Z=0,x]\). Substitution and collection of terms give the right side. Averaging the conditional covariance over strata therefore yields

$$ \beta_{\text{2SLS}} = \frac{\sum_x \pi_x q_x(1-q_x)\Delta Y_x} {\sum_x \pi_x q_x(1-q_x)\Delta D_x}, $$

provided the denominator is nonzero. Under conditional independence and exclusion, the reduced-form difference in each stratum is the complier share times the complier average treatment effect. Monotonicity gives \(\Delta D_x=P(D(1)>D(0)\mid X=x)\), and the exclusion restriction means that only compliers’ treatment changes can generate a reduced-form effect. Thus, for every stratum with \(\Delta D_x>0\), \(\Delta Y_x=\Delta D_x\tau_x\). If \(\Delta D_x=0\), there are no compliers in that stratum under monotonicity; its reduced form is also zero, but \(\tau_x\) is not defined there.

Theorem: If the stated assumptions hold, \(X\) is saturated in the 2SLS regression, and the overall first stage is positive, then
$$ \beta_{\text{2SLS}}=\sum_{x:\,\Delta D_x>0}\lambda_x\tau_x, \qquad \lambda_x= \frac{\pi_x q_x(1-q_x)\Delta D_x} {\sum_j\pi_jq_j(1-q_j)\Delta D_j}. $$
The sum defining the weights in the denominator runs over all strata; strata with \(\Delta D_x=0\) contribute zero. The weighted-average sum runs only over strata with \(\Delta D_x>0\), where \(\tau_x\) is defined. Under monotonicity, positive overlap, and a positive overall first stage, these weights are nonnegative and sum to one.

This formulation handles zero-first-stage strata directly: no undefined local effect is multiplied by a zero weight. Such a stratum contributes neither to the numerator nor the denominator. It does not receive a LATE in this decomposition.

Worked Example: Calculating the 2SLS Weights

Worked Example: Calculating the 2SLS Weights

Suppose a hypothetical population has two covariate strata. In stratum A, \(\pi_A=0.60\), \(q_A=0.25\), and \(\Delta D_A=0.20\). In stratum B, \(\pi_B=0.40\), \(q_B=0.50\), and \(\Delta D_B=0.10\). Assume the IV conditions hold, including monotonicity, and that the stratum-specific LATEs are \(\tau_A=0.30\) outcome units and \(\tau_B=-0.20\) outcome units. These LATEs imply reduced forms \(\Delta Y_A=0.20(0.30)=0.06\) and \(\Delta Y_B=0.10(-0.20)=-0.02\) outcome units.

The unnormalized weight for A is

$$ 0.60(0.25)(0.75)(0.20)=0.0225. $$

For B it is

$$ 0.40(0.50)(0.50)(0.10)=0.0100. $$

The denominator is \(0.0225+0.0100=0.0325\), so \(\lambda_A=0.0225/0.0325=0.6923\) and \(\lambda_B=0.0100/0.0325=0.3077\). Therefore,

$$ \beta_{\text{2SLS}} =0.6923(0.30)+0.3077(-0.20) =0.1462 $$

outcome units per treatment. Directly using the reduced forms gives the same result:

$$ \frac{0.60(0.25)(0.75)(0.06)+0.40(0.50)(0.50)(-0.02)} {0.0325} = \frac{0.00675-0.00200}{0.0325} =0.1462. $$

The negative LATE in B does not make the weights negative. It makes B’s contribution to the weighted average negative. The coefficient is an average over the stratum-specific complier effects, not necessarily an effect that applies to every stratum or every person.

What Determines the Weights?

Each unnormalized weight is the product of three factors: the population share \(\pi_x\), the within-stratum instrument variance \(q_x(1-q_x)\), and the stratum’s first-stage change \(\Delta D_x\). Under monotonicity, the first stage is the share of compliers in that stratum. Consequently, the coefficient gives more weight to strata that are more prevalent, have more variation in instrument assignment, or have a larger complier share. It is not generally a simple average across strata.

The instrument variance factor is largest at \(q_x=0.5\) and approaches zero as \(q_x\) approaches zero or one. A stratum can contain many compliers yet contribute little to this 2SLS estimand if the instrument almost never varies there. Conversely, a smaller stratum may receive substantial weight if it has a strong first stage and considerable instrument variation.

Worked Example: Same First Stage, Different Instrument Propensities

Consider two hypothetical strata with equal population shares, \(\pi_1=\pi_2=0.50\), equal first stages, \(\Delta D_1=\Delta D_2=0.20\), and LATEs \(\tau_1=0.10\) and \(\tau_2=0.50\) outcome units. Let \(q_1=0.10\) and \(q_2=0.50\). The unnormalized weights are

$$ u_1=0.50(0.10)(0.90)(0.20)=0.0090, \qquad u_2=0.50(0.50)(0.50)(0.20)=0.0250. $$

Thus \(\lambda_1=0.0090/0.0340=0.2647\) and \(\lambda_2=0.0250/0.0340=0.7353\). The 2SLS coefficient is

$$ \beta_{\text{2SLS}} =0.2647(0.10)+0.7353(0.50) =0.3941 $$

outcome units per treatment. The strata have equal population shares and equal first stages, yet their 2SLS weights differ because the instrument has more within-stratum variation in stratum 2. This calculation assumes overlap in both strata and the IV assumptions stated above; it does not imply that 2SLS is estimating the population average treatment effect.

Zero First Stages and the Scope of the Average

A stratum with \(\Delta D_x=0\) has zero unnormalized weight. Under monotonicity, this means that the complier share is zero, so the stratum-specific complier effect \(\tau_x\) is undefined: there is no complier population on which to define that conditional average. The zero weight indicates that the stratum does not contribute to this 2SLS estimand, not that its treatment effect is known to be zero.

Worked Example: A Stratum With No First Stage

Suppose a hypothetical analysis has three strata with \((\pi_x,q_x,\Delta D_x)\) equal to \((0.50,0.40,0.20)\), \((0.30,0.50,0.10)\), and \((0.20,0.30,0)\). Under monotonicity, the third stratum has no compliers. The first two unnormalized weights are

$$ u_1=0.50(0.40)(0.60)(0.20)=0.0240, \qquad u_2=0.30(0.50)(0.50)(0.10)=0.00750, \qquad u_3=0. $$

The normalized weights are \(\lambda_1=0.0240/0.0315=0.7619\) and \(\lambda_2=0.00750/0.0315=0.2381\). If the corresponding LATEs are \(0.20\) and \(0.40\) outcome units, the 2SLS coefficient is

$$ 0.7619(0.20)+0.2381(0.40)=0.2476 $$

outcome units per treatment. There is no \(\tau_3\) term: \(\tau_3\) is undefined because the third stratum has no compliers. Its zero first stage gives it no contribution to either the reduced-form numerator or the first-stage denominator.

Conditions That Preserve the Weight Interpretation

The nonnegative-weight result is conditional on the design and specification, not a universal property of every 2SLS regression. The main conditions are:

  • One binary instrument. The derivation uses a single \(Z\in\{0,1\}\), whose within-stratum variance is \(q_x(1-q_x)\).
  • Conditional independence and exclusion. These connect stratum-specific reduced forms to treatment effects among compliers rather than to direct effects of the instrument or confounding.
  • Monotonicity. This rules out defiers and makes each first stage a nonnegative complier share. Without it, first stages can have other interpretations and the weights need not be nonnegative.
  • Saturated covariate controls. The formula uses the conditional instrument residual \(Z-q_x\) in each stratum. Merely entering a restricted, such as linear, function of \(X\) need not produce these stratum-specific residuals or this decomposition.
  • Overlap and a nonzero overall first stage. Each included stratum must have instrument variation to identify a within-stratum contrast, and the total first-stage denominator must be positive for the 2SLS coefficient to be defined.

If the covariate adjustment does not saturate the strata, a regression may still produce a 2SLS coefficient, but it need not equal the weighted average derived here. Likewise, if the exclusion restriction or instrument independence fails, an algebraic ratio may remain computable while losing its interpretation as an average of complier effects.

Common Mistake: Calling the Coefficient an ATE

A common but incorrect argument is: “2SLS gives one coefficient, so it must be the average treatment effect for everyone.” The coefficient instead averages effects for the instrument-induced treatment changers represented in the relevant strata, with weights determined by population prevalence, instrument variation, and first-stage size. People whose treatment never changes with the instrument do not directly identify their own treatment effects through this IV comparison.

Another mistake is to include a stratum with zero first stage in the LATE sum and write its term as a zero weight multiplied by an undefined \(\tau_x\). The correction is to sum only over strata with \(\Delta D_x>0\). Zero-first-stage strata contribute zero to the ratio, but their local complier effects are not defined by this design.

Key takeaway: With one binary instrument and saturated covariate controls, 2SLS is a convex average of stratum-specific LATEs when conditional independence, exclusion, monotonicity, overlap, and a nonzero first stage hold. The weights reveal which instrument-induced treatment changes drive the coefficient; they do not turn it into a population-wide average effect.

Check Your Understanding

Use the assumptions and formulas above to answer the following questions.

  1. In a stratum with \(\pi_x=0.40\), \(q_x=0.25\), and \(\Delta D_x=0.20\), calculate its unnormalized weight.
  2. Why can two equally prevalent strata with the same first stage receive different 2SLS weights?
  3. Under monotonicity, what does a zero first stage imply about the complier share, and why is the stratum-specific LATE undefined?
  4. State the conditions under which the normalized weights form a nonnegative weighted average.
  5. Why does a covariate-adjusted 2SLS coefficient generally not equal the population average treatment effect?
Clinical Biostats